Oh Oh No Ozempic? | #385
from Faith and Economics Hosted by Gwartney Institute
A new class of drugs, GLP-1 inhibitors (Ozempic being the most recognizable) has seemingly taken the world by storm. If the hype is to be believed, there seems to be enormous upsides and zero downsides to these new wonders of chemistry. Is that really the case, or might there be reason for caution? Join the Gwartney Institute for an insightful discussion on the promise and perils of these powerful peptides.
Embed this episode
No transcript yet.
Similar podcasts
Frequently asked questions
How long is this episode of Faith and Economics?
This episode is 34 minutes long.
When was this Faith and Economics episode published?
This episode was published on March 15, 2026.
Can I download this Faith and Economics episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.